MARCH 23 WEBINAR DETAILS
Advances in Hemophilia
ISTH Core Curriculum 6.1, 6.2, 6.11 - Hemophilia
March 23, 2016 16:00 - 17:00 UTC
In conjunction with the World Federation of Hemophilia (WFH)
This webinar is free to all. Join the ISTH Academy for free to obtain limited access, or become an ISTH member for complete access to the Academy
Peter Collins - "Clinical trials of enhanced half-life FVIII and FIX"
Gary Gilbert - "Experimental therapies"
Moderator: David Lillicrap
Peter Collins, MBBS, MD, FRCP, FRCPath
Peter Collins is a professor in haematology at the School of Medicine of Cardiff University and an honorary consultant haematologist and director of the Arthur Bloom Haemophilia Centre at the University Hospital of Wales, Cardiff.
His research interests include acquired haemophilia, prophylactic treatment in haemophilia, factor VIII inhibitors, pharmacokinetics of factor VIII and IX, haemostatic impairment during postpartum haemorrhage and the role of phospholipids in controlling coagulation.
Gary E. Gilbert
Dr. Gary E. Gilbert is chief of hematology and oncology at VA Boston Healthcare System. He has a laboratory research program where his work has focused on the interface between factor VIII and platelet membranes. He is also Chief Operating Officer at Little Sparrows Technologies, LLC, in Boston, MA. He received his medical degree from the Loma Linda University School of Medicine in Loma Linda, CA. Following his residencies at Loma Linda University Medical Center and at Riverside General Hospital- University Medical Center in Riverside, CA, Dr. Gilbert served a clinical fellowship in hematology/oncology and a research fellowship in hemostasis and thrombosis under Drs. Bruce and Barbara Furie at Tufts/New England Medical Center in Boston, MA.
Dr. Gilbert’s current research focuses on understanding the mechanisms through which the activity of factor VIII is regulated by the platelet cell membrane.
Dr. Gilbert is a reviewer for seven medical journals. His own research has appeared in Blood, Science, J. Thrombosis and Haemostasis, Thrombosis and Haemostasis, J. Biological Chemistry, Biochemical Journal, Biochemistry, and PLoS One.
Dr. Lillicrap is a Professor in the Department of Pathology and Molecular Medicine at Queen’s University, Kingston, Canada. Since 2000, he has been the recipient of a Canada Research Chair in Molecular Hemostasis and is a past Career Investigator of the Heart and Stroke Foundation of Ontario. In 2013, he was elected to the Fellowship of the Royal Society of Canada. He is the Chair of the Research Committee of the World Federation of Hemophilia (WFH) and is a member of the Medical Advisory Board of the WFH. He served a three year term as the Chairperson of the International Society on Thrombosis and Haemostasis’ Scientific and Standardization sub-committee (SSC) on von Willebrand Factor, and is the immediate Past-Chair of the Society’s SSC. He was recently elected to a five-year term as a Member of the ISTH Council. From 2008-2014, he served as an Associate Editor of the journal Blood, and he is also a member of the editorial board of the British Journal of Haematology. His research program relates to molecular aspects of the hemostatic system, with particular emphasis on novel therapeutic approaches and immunological complications of hemophilia A, and the genetics, biology and pathobiology of von Willebrand factor.
|Sponsored by an unrestricted
educational grant from: